JPMorganChase to Expand Paris Office Space
15.5.2025 10:30:00 CEST | Business Wire | Press Release
JPMorganChase today announces that it has signed a lease on a new building in Paris at 37 Place du Marché Saint-Honoré as the firm has passed over 1,000 employees in the city. The new office is situated behind the bank’s headquarters at 14 Place Vendôme, and is opposite 21 Place du Marché Saint-Honoré, where the bank also has employees. While this investment will see the firm reduce the buildings it occupies in central Paris from six to just three, overall office space will increase significantly, creating a much better working environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515443526/en/
The new building will open in early 2027 after a complete refurbishment, at which point all surplus buildings will be exited. Many employees will relocate to the new building to free up space in 14 Place Vendôme in particular, and to improve client facilities.
Jamie Dimon, CEO of JPMorganChase said: “This new investment reflects the runaway success we have made of our business in Paris over the last five years in particular. Even beyond our expectations, we have continued to attract some of our best people to the city and we have hired more people locally too. Between this new building, and our historic home at 14 Place Vendôme, we will be ready for the next generation of bankers.”
Designed by prominent architect, Ricardo Bofill, the 16,000 square-metre building will create a flexible and collaborative workplace, providing a world-class experience for employees with large open floors and modern amenities across five storeys.
President Emmanuel Macron, said: “Our strategy to make Paris the most attractive location in the EU for financial services companies continues to pay off. JPMorganChase has had a long term presence and relationship with the Republic of France, and has been a model corporate citizen as it has expanded in recent years, investing in our local communities in Paris as it has done so.”
This announcement coincides with the 20th anniversary of the firm’s flagship Global Markets Conference, which brings together companies and investors in Paris each year, underscoring the importance of Paris as a financial centre. When it is ready, the bank’s Sales & Trading team will be among the first to move into the new building at 37 Place du Marché Saint-Honoré.
Modern workplace prioritising employee well-being
37 Place du Marché Saint-Honoré will be designed to adapt to the future of work and will feature a mix of formal and informal meeting spaces to encourage innovative thinking and collaboration. It will also house a café space for employees to gather and socialise.
Employees also have access to best-in-class wellness experiences. From natural lighting to the use of air quality sensors and biophilic design, 37 Place du Marché Saint-Honoré will support employees’ physical and emotional well-being. And with facilities including nursing and meditation rooms, terraces and roof-tops to provide much-coveted private outdoor space in central Paris, there will be plenty of opportunity to achieve balance in the working day.
In line with JPMorganChase’s global sustainability commitments across its real estate portfolio, the aim is for the building to achieve advanced environmental and wellness certifications including: BREEM (Excellent), Well Core & Shell (Gold), Wiredscore (Platinum), and SmartScore (Silver).
The refurbishment is already underway under the management of CBRE Investment Management, which is looking to set a new benchmark for sustainable, intelligent and high-performance offices in the city.
Serving Paris and France
For more than 150 years, JPMorganChase has served its clients and local communities in Greater Paris in good and tough times — from helping citizens take part in the country’s economic growth to supporting the Allies during World War I. Today, as one of the longest operating American banks in France and a significant employer, we remain committed to that mission, strengthening local communities by lifting up individuals as well as institutions, including small, medium, and large companies, schools and healthcare facilities.
Since 2018 when it announced major philanthropic partnerships in Seine-Saint-Denis, the bank has invested $100 million in the region through local partnerships. Most recently, this included the creation of Bpifrance Spark Fund, an investment initiative together with Bpifrance, aimed at providing capital to gender diverse private investment firms and funds investing in strategies that are positively impacting society and communities.
With more than 1,000 employees in France, the bank offers services in commercial and investment banking, sales & trading, private banking and asset management. It has 1,000 employees in Paris who come from 61 different countries, and so it benefits from a true melting pot of global ideas.
About JPMorganChase
JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America (“U.S.”), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $351 billion in stockholders’ equity as of March 31, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world’s most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250515443526/en/
Contacts
Media Contacts:
Anne Roppé
+33 1 40 15 47 71
anne.roppe@jpmorgan.com
Patrick Burton
+44 20 7134 9041
patrick.o.burton@jpmorgan.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom